India Aims to Diversify Pharma Exports Amid U.S. Tariff Concerns

India’s pharmaceutical industry is actively seeking to diversify its export destinations, with a renewed focus on Russia, Brazil, and the Netherlands as key growth markets. The move comes against the backdrop of rising geopolitical and trade uncertainty with the United States — even though pharma products currently remain exempt from the recently imposed 50% tariffs on select Indian goods.

The U.S. continues to be the single largest market for Indian pharma, accounting for more than one-third of exports, about $10.5 billion in FY2025. This heavy reliance leaves Indian drugmakers vulnerable to policy shifts in Washington.

Key Secondary Markets (FY2025):

Industry executives say India’s strong manufacturing capacity and cost competitiveness could allow exports to these secondary markets to grow by up to 20% over the next few years. However, they caution that these markets cannot fully replace U.S. revenues, highlighting that the strategy is about risk diversification, not substitution.

Tackling Regulatory Barriers

A major challenge remains the regulatory approval process in these regions. To address this, Indian pharma companies and government officials plan to use the International Pharmaceutical Exhibition (NPHEX) in New Delhi as a platform to engage directly with regulators and buyers from these target markets.

Why It Matters

India’s pharma industry, known as the “pharmacy of the world” — supplies affordable generics globally. But its dependency on the U.S. makes it vulnerable to trade policy shocks. A broader export footprint could:

Investor Perspective

For investors, this shift signals a medium- to long-term positive. While diversification may not immediately offset U.S. dependence, it reduces downside risk if tariffs or stricter regulations are imposed in the future. Companies with stronger European and LATAM pipelines (e.g., Sun Pharma, Dr. Reddy’s, Cipla) may benefit the most from early-mover advantages.